larger) database, the results did not alter conclusions reached previously. Table 7: Summary of consideration of eCry3.1Ab, mCry3Aa2 and PAT in previous FSANZ safety assessments Consideration Sub-section eCry3.1Ab mCry3Aa2 PAT Amino acid This application This application This application - – – sequence using search using search using search similarity to updated in March updated in March updated in April protein toxins 2015 2015 2015 Potential In vitro A1060 A564 A1080 digestibility (FSANZ 2012) (FSANZ 2006a) (FSANZ 2013a) toxicity A1060 A564 A1080 Stability to heat (FSANZ 2012) (FSANZ 2006a) (FSANZ 2013a) Acute oral A1060 A564 A1080 toxicity (FSANZ 2012) (FSANZ 2006a) (FSANZ 2013a)
larger) database, the results did not alter conclusions reached previously. Table 7: Summary of consideration of eCry3.1Ab, mCry3Aa2 and PAT in previous FSANZ safety assessments Consideration Sub-section eCry3.1Ab mCry3Aa2 PAT Potential toxicity Amino acid sequence similarity to protein toxins This application – using search updated in March 2015 This application – using search updated in March 2015 This application - using search updated in April 2015 In vitro digestibility A1060 (FSANZ 2012) A564 (FSANZ 2006a) A1080 (FSANZ 2013a) Stability to heat A1060 (FSANZ 2012) A564 (FSANZ 2006a) A1080 (FSANZ 2013a) Acute oral toxicity A1060 (FSANZ 2012) A564 (FSANZ 2006a) A1080 (FSANZ 2013a)